×
About 2,468 results

ALLMedicine™ Genital Warts Center

Research & Reviews  664 results

Alteration of Na/H exchange regulatory factor-1 protein levels in anogenital lesions po...
https://doi.org/10.1016/j.virol.2022.09.004
Virology Saponaro C, Galati L et. al.

Oct 1st, 2022 - Mucosal high-risk (HR) human papillomaviruses (HPV) are associated with anogenital carcinogenesis. The products of two early genes, E6 and E7, act as major viral oncoproteins. Functional studies in experimental models showed that HPV16 E6 induces ...

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
https://clinicaltrials.gov/ct2/show/NCT05285826

Sep 29th, 2022 - This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be strati...

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
https://clinicaltrials.gov/ct2/show/NCT03180034

Sep 23rd, 2022 - PRIMARY OBJECTIVES: I. For each vaccine separately, to evaluate non-inferiority of one compared to two vaccination doses in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. II....

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
https://clinicaltrials.gov/ct2/show/NCT05435209

Sep 22nd, 2022 - Background: Genital Human Papilloma Virus (HPV) infections occur rapidly after sexual debut, and immunosuppressed individuals are at greater risk for incident and persistent infection. HPV vaccine contains virus-like particles (VLP), which are hig...

Vaccination with human alphapapillomavirus-derived L2 multimer protects against human b...
https://doi.org/10.1016/j.virol.2022.08.006
Virology Olczak P, Wong M et. al.

Sep 8th, 2022 - Human alphapapillomaviruses (αHPV) infect genital mucosa, and a high-risk subset is a necessary cause of cervical cancer. Licensed L1 virus-like particle (VLP) vaccines offer immunity against the nine most common αHPV associated with cervical canc...

see more →

Guidelines  5 results

Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809.
https://doi.org/10.1097/AOG.0000000000004000
Obstetrics and Gynecology;

Aug 1st, 2020 - Human papillomavirus (HPV) causes significant morbidity and mortality in women and men. The HPV vaccine significantly reduces the incidence of anogenital cancer and genital warts in women and in men. Human papillomavirus vaccines are among the mos...

Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination.
https://doi.org/10.1097/AOG.0000000000002111
Obstetrics and Gynecology;

May 26th, 2017 - Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and geni...

Committee Opinion No. 704: Human Papillomavirus Vaccination.
https://doi.org/10.1097/AOG.0000000000002052
Obstetrics and Gynecology;

Mar 28th, 2017 - Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and geni...

Sexually transmitted diseases treatment guidelines, 2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885289
MMWR. Recommendations and Reports : Morbidity and Mortali... Workowski KA, Bolan GA et. al.

Jun 5th, 2015 - These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30-M...

Committee opinion no. 588: human papillomavirus vaccination.
https://doi.org/10.1097/01.AOG.0000444458.00612.6b
Obstetrics and Gynecology;

Feb 21st, 2014 - The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescen...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  84 results

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
https://clinicaltrials.gov/ct2/show/NCT05285826

Sep 29th, 2022 - This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be strati...

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
https://clinicaltrials.gov/ct2/show/NCT03180034

Sep 23rd, 2022 - PRIMARY OBJECTIVES: I. For each vaccine separately, to evaluate non-inferiority of one compared to two vaccination doses in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. II....

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
https://clinicaltrials.gov/ct2/show/NCT05435209

Sep 22nd, 2022 - Background: Genital Human Papilloma Virus (HPV) infections occur rapidly after sexual debut, and immunosuppressed individuals are at greater risk for incident and persistent infection. HPV vaccine contains virus-like particles (VLP), which are hig...

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT05208710

Sep 7th, 2022 - Infections with one of 15 human papillomavirus (HPV) types are considered the main risk factor for the development of certain anogenital cancers. In addition, these HPV types are also suspected to be causatively involved in oropharyngeal cancer. T...

Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
https://clinicaltrials.gov/ct2/show/NCT02119702

Aug 30th, 2022 - AMP Up aims to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition into adulthood. A group of uninfected young adults from a similar sociodemographic background and ag...

see more →

News  215 results

Physicians Shy From Notifying Patients' Partners of STIs
https://www.medscape.com/viewarticle/976068

Jun 23rd, 2022 - Less than 10% of family physicians in British Columbia, Canada, contact the partners of patients whom they have diagnosed with sexually transmitted infections (STIs), new data indicate. In an online survey of almost 150 family physicians throughou...

Commentary: Adolescents are undertested for STIs
https://www.mdedge.com/pediatrics/article/257708/commentary-adolescents-are-undertested-stis
Christopher J. Harrison, MD

Apr 11th, 2022 - Despite current guidelines permitting opt-out STI screening and the ability in most states to treat adolescents 13 years old and older for STIs without parental notification, STI testing rates remain low. The articles about the 2019 survey raise s.

Labial growth
https://www.mdedge.com/familymedicine/article/252620/dermatology/labial-growth
MDedge Family Medicine;

Mar 10th, 2022 - White-to-pink friable plaques occurring acutely in the vulva is concerning for one form of secondary syphilis that affects mucous membranes: condyloma lata. Known as the great imitator for its variety of clinical presentations, syphilis is a sexua.

HPV Vaccination Rates Continue to Climb Among Young Adults in US
https://www.medscape.com/viewarticle/950043

Apr 27th, 2021 - Although vaccination rates against the human papillomavirus (HPV) remain low for young adults across the United States, the number of self-reported HPV vaccinations among women and men between the ages of 18 and 21 years has markedly increased sin...

FDA Approvals of HPV Vaccine and NGS Assay, Priority Review in Myeloma, and More
https://www.onclive.com/view/fda-approvals-of-hpv-vaccine-and-ngs-assay-priority-review-in-myeloma-and-more

Apr 2nd, 2021 - Today- FDA approvals of an HPV vaccine and a next-generation sequencing assay, a priority review designation in multiple myeloma, and an ODAC recommendation for a biosimilar. Welcome to OncLive News Network! I’m Gina Columbus. The FDA has...

see more →

Patient Education  12 results see all →